RU2019101298A - Антисмысловые олигонуклеотиды для модулирования экспрессии htra1 - Google Patents

Антисмысловые олигонуклеотиды для модулирования экспрессии htra1 Download PDF

Info

Publication number
RU2019101298A
RU2019101298A RU2019101298A RU2019101298A RU2019101298A RU 2019101298 A RU2019101298 A RU 2019101298A RU 2019101298 A RU2019101298 A RU 2019101298A RU 2019101298 A RU2019101298 A RU 2019101298A RU 2019101298 A RU2019101298 A RU 2019101298A
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
antisense oligonucleotide
salt
Prior art date
Application number
RU2019101298A
Other languages
English (en)
Other versions
RU2019101298A3 (ru
Inventor
Роберто ЯКОНЕ
Петер ХАГЕДОРН
Сюзанн КАММЛЕР
Сёрен Оттосен
Синдри ТРАУСТАСОН
Хайди ХУДЛБУШ
Люкке ПЕДЕРСЕН
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2019101298A publication Critical patent/RU2019101298A/ru
Publication of RU2019101298A3 publication Critical patent/RU2019101298A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Claims (19)

1. Антисмысловой олигонуклеотид формулы: TsAsTststsascscstsgsgstsTsGsTsT (SEQ ID NO 143), где заглавная буква представляет нуклеозидное звено LNA, строчная буква представляет нуклеозидное звено ДНК, подстрочный символ s представляет фосфоротиоатную межнуклеозидную связь.
2. Антисмысловой олигонуклеотид по п. 1, где все нуклеозиды LNA представляют собой бета-D-окси нуклеозиды LNA.
3. Антисмысловой олигонуклеотид по п. 1, где антисмысловой олигонуклеотид имеет формулу:
Figure 00000001
4. Фармацевтически приемлемая соль антисмыслового олигонуклотида по любому из пп. 1-3.
5. Фармацевтически приемлемая соль по п. 4, где данная соль представляет собой натриевую соль.
6. Фармацевтически приемлемая соль по п. 4, где данная соль представляет собой калиевую соль.
7. Фармацевтическая композиция, содержащая антисмысловой олигонуклеотид по любому из пп. 1-3; и фармацевтически приемлемый разбавитель, носитель, соль и/или адъювант.
8. Фармацевтическая композиция по п. 7, где данная фармацевтическая композиция содержит фармацевтически приемлемый разбавитель.
9. Фармацевтическая композиция по п. 8, где фармацевтически приемлемый разбавитель представляет собой фосфатно-солевой буферный раствор.
10. Фармацевтическая композиция по любому из пп. 7-9, где олигонуклеотид находится в форме фармацевтически приемлемой соли.
11. Фармацевтическая композиция, содержащая фармацевтически приемлемую соль по любому из пп. 4-6; и фармацевтически приемлемый разбавитель, носитель, соль и/или адъювант.
12. Фармацевтическая композиция по любому из пп. 7-11, в которой фармацевтически приемлемая соль представляет собой натриевую соль или калиевую соль.
13. Антисмысловой олигонуклеотид по любому из пп. 1-3 или фармацевтически приемлемая соль по любому из пп. 4-6, фармацевтическая композиция по любому из пп. 7-12 для применения в медицине.
14. Антисмысловой олигонуклеотид по любому из пп. 1-3 или фармацевтически приемлемая соль по любому из пп. 4-6, или фармацевтическая композиция по любому из пп. 7-12 для применения в лечении макулодистрофии.
15. Применение антисмыслового олигонуклеотида по любому из пп. 1-3 или фармацевтически приемлемой соли по любому из пп. 4-6, или фармацевтической композиции по любому из пп. 7-12 для получения лекарственного средства для лечения или предупреждения макулодистрофии.
16. Способ лечения или предупреждения макулодистрофии у субъекта, страдающего от макулодистрофии, включающий введение субъекту терапевтически эффективного количества антисмыслового олигонуклеотида по любому из пп. 1-3 или фармацевтически приемлемой соли по любому из пп. 4-6, или фармацевтической композиции по любому из пп. 7-12.
17. Антисмысловой олигонуклеотид, фармацевтически приемлемая соль, фармацевтическая композиция по любому из пп. 13-14, применение по пп. 15 или способ по п. 16, где заболевание выбрано из влажной AMD (возрастная макулодистрофия), сухой AMD, географической атрофии и промежуточной dAMD.
18. Способ in vivo или in vitro модулирования экспрессии HTRA1 в клетке-мишени, которая экспрессирует HTRA1, причем указанный способ включает введение в указанную клетку антисмыслового олигонуклеотида, фармацевтически приемлемой соли или фармацевтической композиции в эффективном количестве.
RU2019101298A 2016-07-01 2017-06-28 Антисмысловые олигонуклеотиды для модулирования экспрессии htra1 RU2019101298A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16177508 2016-07-01
EP16177508.5 2016-07-01
EP17170129.5 2017-05-09
EP17170129 2017-05-09
PCT/EP2017/065937 WO2018002105A1 (en) 2016-07-01 2017-06-28 Antisense oligonucleotides for modulating htra1 expression

Publications (2)

Publication Number Publication Date
RU2019101298A true RU2019101298A (ru) 2020-08-03
RU2019101298A3 RU2019101298A3 (ru) 2021-01-26

Family

ID=59295175

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019101298A RU2019101298A (ru) 2016-07-01 2017-06-28 Антисмысловые олигонуклеотиды для модулирования экспрессии htra1

Country Status (21)

Country Link
US (2) US10519450B2 (ru)
EP (1) EP3478839A1 (ru)
JP (3) JP7060525B2 (ru)
KR (1) KR20190025970A (ru)
CN (1) CN109415732B (ru)
AU (1) AU2017289204A1 (ru)
BR (1) BR112018077321A2 (ru)
CA (1) CA3026855A1 (ru)
CL (1) CL2018003698A1 (ru)
CO (1) CO2018013240A2 (ru)
CR (1) CR20180606A (ru)
IL (1) IL263489A (ru)
MA (1) MA45620A (ru)
MX (1) MX2018015722A (ru)
PE (1) PE20190381A1 (ru)
PH (1) PH12018502707A1 (ru)
RU (1) RU2019101298A (ru)
SG (2) SG10202005885VA (ru)
TW (1) TW201803990A (ru)
WO (1) WO2018002105A1 (ru)
ZA (1) ZA201808291B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
EP3472149B1 (en) 2016-06-21 2023-08-30 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
EP3478839A1 (en) 2016-07-01 2019-05-08 H. Hoffnabb-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
EP3728590A1 (en) 2017-12-22 2020-10-28 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
TW201929870A (zh) 2017-12-22 2019-08-01 丹麥商羅氏創新中心哥本哈根有限公司 包含二硫代磷酸酯核苷間連結之寡核苷酸
MX2020005754A (es) 2017-12-22 2020-08-20 Roche Innovation Ct Copenhagen As Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato.
EP3752612A4 (en) 2018-02-12 2021-11-10 Ionis Pharmaceuticals, Inc. MODIFIED COMPOUNDS AND USES THEREOF
WO2020007772A1 (en) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting gbp-1
WO2020109343A1 (en) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2020109344A1 (en) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Occular administration device for antisense oligonucleotides

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
DE04020014T1 (de) 1997-09-12 2006-01-26 Exiqon A/S Bi-zyklische - Nukleosid,Nnukleotid und Oligonukleotid-Analoga
AU5290499A (en) 1998-08-03 2000-02-28 Novartis Ag Human htra serine protease
IL144338A0 (en) 1999-02-12 2002-05-23 Sankyo Co Nucleoside and oligonucleotide analogues and pharmaceutical compositions containing the same
PT1178999E (pt) 1999-05-04 2007-06-26 Santaris Pharma As Análogos de l-ribo-lna
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
DK3222722T3 (da) 2002-11-18 2019-06-17 Roche Innovation Ct Copenhagen As Antisense-design
ATE538798T1 (de) 2005-05-24 2012-01-15 Isis Pharmaceuticals Inc Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CN101490074B (zh) 2006-05-11 2013-06-26 Isis制药公司 5’-修饰的双环核酸类似物
AU2007277125B2 (en) 2006-07-26 2013-08-01 Yale University Diagnosis and treatment of age related macular degeneration
US20100166743A1 (en) 2006-10-06 2010-07-01 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
EP2913341A1 (en) * 2006-12-22 2015-09-02 University of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
TW200911290A (en) 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
ATE538127T1 (de) 2007-07-05 2012-01-15 Isis Pharmaceuticals Inc 6-disubstituierte bicyclische nukleinsäureanaloga
CA2704787A1 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Genes and polymorphisms associated with amd
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
FR2965278B1 (fr) 2010-09-23 2014-10-10 Univ Caen Basse Normandie Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations
WO2013036868A1 (en) 2011-09-07 2013-03-14 Marina Biotech Inc. Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
EP2850184A4 (en) 2012-05-16 2016-01-27 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION
DK2920307T3 (en) 2012-11-15 2018-07-16 Roche Innovation Ct Copenhagen As ANTI-APOB, ANTISENSE CONJUGATE RELATIONSHIPS
SG10202001808VA (en) 2015-10-30 2020-04-29 Genentech Inc Anti-htra1 antibodies and methods of use thereof
EP3478839A1 (en) 2016-07-01 2019-05-08 H. Hoffnabb-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
US20190284621A1 (en) 2016-11-11 2019-09-19 Roche Innovation Center Copenhagen A/S Therapeutic oligonucleotides capture and detection
US20190055564A1 (en) 2017-06-01 2019-02-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression

Also Published As

Publication number Publication date
TW201803990A (zh) 2018-02-01
RU2019101298A3 (ru) 2021-01-26
CN109415732B (zh) 2024-01-02
JP2019522987A (ja) 2019-08-22
CN109415732A (zh) 2019-03-01
JP7416852B2 (ja) 2024-01-17
PH12018502707A1 (en) 2019-11-11
CL2018003698A1 (es) 2019-04-05
WO2018002105A1 (en) 2018-01-04
IL263489A (en) 2019-01-31
PE20190381A1 (es) 2019-03-08
MX2018015722A (es) 2019-05-27
SG10202005885VA (en) 2020-07-29
ZA201808291B (en) 2019-10-30
JP7060525B2 (ja) 2022-04-26
US10519450B2 (en) 2019-12-31
US20200399641A1 (en) 2020-12-24
CO2018013240A2 (es) 2018-12-14
EP3478839A1 (en) 2019-05-08
JP2024029178A (ja) 2024-03-05
KR20190025970A (ko) 2019-03-12
US20180002701A1 (en) 2018-01-04
CR20180606A (es) 2019-02-14
BR112018077321A2 (pt) 2019-04-24
AU2017289204A1 (en) 2019-01-17
SG11201811554SA (en) 2019-01-30
CA3026855A1 (en) 2018-01-04
JP2022106785A (ja) 2022-07-20
MA45620A (fr) 2019-05-08

Similar Documents

Publication Publication Date Title
RU2019101298A (ru) Антисмысловые олигонуклеотиды для модулирования экспрессии htra1
US11788089B2 (en) Compositions and methods for modulating MECP2 expression
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
RU2018134379A (ru) Олигонуклеотиды для понижения экспрессии pd-l1
HRP20191232T1 (hr) Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
ES2697606T3 (es) Compuestos de oligonucleótido inmunorregulador (IRO) para modular la respuesta inmunitaria basada en un receptor tipo Toll
HRP20200163T1 (hr) Antisens oligomeri i konjugati koji ciljno djeluju na pcsk9
JP2017536366A5 (ru)
JP2017505623A5 (ru)
RU2017127609A (ru) Антисмысловые олигомеры тау-белка и их применение
JP2018533954A5 (ru)
RU2017139121A (ru) Композиции для модулирования экспрессии c9orf72
WO2013173637A1 (en) Compositions and methods for modulating gene expression
JP2018512110A5 (ru)
WO2013173635A1 (en) Compositions and methods for modulating gene expression
WO2013173599A1 (en) Compositions and methods for modulating hemoglobin gene family expression
RU2016139108A (ru) Антисмысловые нуклеиновые кислоты
JP2017513469A5 (ru)
CA2873776A1 (en) Compositions and methods for modulating pten expression
RU2019130898A (ru) Композиции для модуляции экспрессии атаксина 2
CN107002082B (zh) 反义寡核苷酸作为tgf-r信号传导的抑制剂
JP2017510271A5 (ru)
AU2009302468A1 (en) Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
RU2020115761A (ru) МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В
RU2018113276A (ru) Антисмысловая нуклеиновая кислота

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210610